AAPL295.18+5.82 (+2.01%) ▲|ABBV249.56-2.08 (-0.83%) ▼|ABT92.85+2.11 (+2.33%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE212.61+7.59 (+3.70%) ▲|AMAT663.31-59.69 (-8.26%) ▼|AMD551.15-29.77 (-5.12%) ▼|AMGN360.80-1.32 (-0.36%) ▼|AMT165.55+1.98 (+1.21%) ▲|AMZN241.81+3.47 (+1.46%) ▲|AVGO370.59-7.16 (-1.90%) ▼|AXP348.72+10.47 (+3.10%) ▲|BA217.87+1.40 (+0.65%) ▲|BAC58.23+1.25 (+2.19%) ▲|BKNG184.71+6.47 (+3.63%) ▲|BLK978.17+16.61 (+1.73%) ▲|BMY56.66-0.97 (-1.67%) ▼|BNY146.74+2.13 (+1.47%) ▲|BRK-B503.15+2.76 (+0.55%) ▲|C140.73+0.77 (+0.55%) ▲|CAT1,019.34-45.56 (-4.28%) ▼|CL92.49+0.81 (+0.88%) ▲|CMCSA24.16-0.39 (-1.59%) ▼|COF204.94+4.32 (+2.15%) ▲|COP103.74-0.22 (-0.21%) ▼|COST926.70-8.77 (-0.94%) ▼|CRM164.94+8.28 (+5.28%) ▲|CSCO116.33-1.13 (-0.96%) ▼|CVS104.11+0.66 (+0.63%) ▲|CVX166.32+0.56 (+0.34%) ▲|DE631.49-2.84 (-0.45%) ▼|DHR194.76+4.28 (+2.24%) ▲|DIS97.04+0.79 (+0.82%) ▲|DUK126.18-0.40 (-0.32%) ▼|EMR142.47-0.68 (-0.48%) ▼|FDX315.03+1.90 (+0.61%) ▲|GD364.11+9.87 (+2.79%) ▲|GE375.80+2.07 (+0.55%) ▲|GEV1,153.80-21.06 (-1.79%) ▼|GILD126.20-0.15 (-0.11%) ▼|GM76.53-0.56 (-0.72%) ▼|GOOG356.33+3.00 (+0.85%) ▲|GOOGL359.45+2.08 (+0.58%) ▲|GS1,024.23+12.86 (+1.27%) ▲|HD356.34+3.66 (+1.04%) ▲|HON224.19+0.29 (+0.13%) ▲|IBM293.10+11.89 (+4.23%) ▲|INTC129.30-10.33 (-7.40%) ▼|INTU272.00+11.00 (+4.21%) ▲|ISRG404.99+7.31 (+1.84%) ▲|JNJ252.34-1.63 (-0.64%) ▼|JPM334.34+7.01 (+2.14%) ▲|KO81.76+0.49 (+0.60%) ▲|LIN536.04+17.10 (+3.30%) ▲|LLY1,191.20-8.24 (-0.69%) ▼|LMT521.48+12.02 (+2.36%) ▲|LOW225.28+4.79 (+2.17%) ▲|LRCX396.34-36.99 (-8.54%) ▼|MA528.55+14.95 (+2.91%) ▲|MCD270.44+0.13 (+0.05%) ▲|MDLZ59.17+1.33 (+2.29%) ▲|MDT79.40+1.17 (+1.50%) ▲|META618.43+55.14 (+9.79%) ▲|MMM161.68-0.23 (-0.14%) ▼|MO71.96+0.01 (+0.01%) ▲|MRK126.59-1.91 (-1.49%) ▼|MS211.51+2.47 (+1.18%) ▲|MSFT384.67+11.65 (+3.12%) ▲|MU1,053.73-100.57 (-8.71%) ▼|NEE86.95-0.82 (-0.93%) ▼|NFLX73.39+1.99 (+2.78%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.65+6.37 (+6.42%) ▲|NVDA196.89-3.20 (-1.60%) ▼|ORCL145.11-1.44 (-0.98%) ▼|PEP140.05+4.65 (+3.43%) ▲|PFE23.94-0.15 (-0.60%) ▼|PG146.37-0.27 (-0.18%) ▼|PLTR127.19+10.52 (+9.02%) ▲|PM178.43-2.48 (-1.37%) ▼|QCOM185.52+0.73 (+0.39%) ▲|RTX191.39+1.66 (+0.87%) ▲|SBUX101.57-0.63 (-0.61%) ▼|SCHW94.40+2.13 (+2.31%) ▲|SO95.79+0.08 (+0.08%) ▲|SPG221.82-1.84 (-0.82%) ▼|T20.64-0.06 (-0.29%) ▼|TMO520.60+19.24 (+3.84%) ▲|TMUS172.53+4.80 (+2.86%) ▲|TSLA429.34+8.74 (+2.08%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.35+1.19 (+1.65%) ▲|UNH421.65+6.02 (+1.45%) ▲|UNP276.15+4.15 (+1.53%) ▲|UPS109.83+2.33 (+2.17%) ▲|USB61.98+1.58 (+2.62%) ▲|V352.39+9.30 (+2.71%) ▲|VZ42.08-0.27 (-0.63%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.05-5.21 (-4.60%) ▼|XOM136.85+0.13 (+0.10%) ▲|AAPL295.18+5.82 (+2.01%) ▲|ABBV249.56-2.08 (-0.83%) ▼|ABT92.85+2.11 (+2.33%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE212.61+7.59 (+3.70%) ▲|AMAT663.31-59.69 (-8.26%) ▼|AMD551.15-29.77 (-5.12%) ▼|AMGN360.80-1.32 (-0.36%) ▼|AMT165.55+1.98 (+1.21%) ▲|AMZN241.81+3.47 (+1.46%) ▲|AVGO370.59-7.16 (-1.90%) ▼|AXP348.72+10.47 (+3.10%) ▲|BA217.87+1.40 (+0.65%) ▲|BAC58.23+1.25 (+2.19%) ▲|BKNG184.71+6.47 (+3.63%) ▲|BLK978.17+16.61 (+1.73%) ▲|BMY56.66-0.97 (-1.67%) ▼|BNY146.74+2.13 (+1.47%) ▲|BRK-B503.15+2.76 (+0.55%) ▲|C140.73+0.77 (+0.55%) ▲|CAT1,019.34-45.56 (-4.28%) ▼|CL92.49+0.81 (+0.88%) ▲|CMCSA24.16-0.39 (-1.59%) ▼|COF204.94+4.32 (+2.15%) ▲|COP103.74-0.22 (-0.21%) ▼|COST926.70-8.77 (-0.94%) ▼|CRM164.94+8.28 (+5.28%) ▲|CSCO116.33-1.13 (-0.96%) ▼|CVS104.11+0.66 (+0.63%) ▲|CVX166.32+0.56 (+0.34%) ▲|DE631.49-2.84 (-0.45%) ▼|DHR194.76+4.28 (+2.24%) ▲|DIS97.04+0.79 (+0.82%) ▲|DUK126.18-0.40 (-0.32%) ▼|EMR142.47-0.68 (-0.48%) ▼|FDX315.03+1.90 (+0.61%) ▲|GD364.11+9.87 (+2.79%) ▲|GE375.80+2.07 (+0.55%) ▲|GEV1,153.80-21.06 (-1.79%) ▼|GILD126.20-0.15 (-0.11%) ▼|GM76.53-0.56 (-0.72%) ▼|GOOG356.33+3.00 (+0.85%) ▲|GOOGL359.45+2.08 (+0.58%) ▲|GS1,024.23+12.86 (+1.27%) ▲|HD356.34+3.66 (+1.04%) ▲|HON224.19+0.29 (+0.13%) ▲|IBM293.10+11.89 (+4.23%) ▲|INTC129.30-10.33 (-7.40%) ▼|INTU272.00+11.00 (+4.21%) ▲|ISRG404.99+7.31 (+1.84%) ▲|JNJ252.34-1.63 (-0.64%) ▼|JPM334.34+7.01 (+2.14%) ▲|KO81.76+0.49 (+0.60%) ▲|LIN536.04+17.10 (+3.30%) ▲|LLY1,191.20-8.24 (-0.69%) ▼|LMT521.48+12.02 (+2.36%) ▲|LOW225.28+4.79 (+2.17%) ▲|LRCX396.34-36.99 (-8.54%) ▼|MA528.55+14.95 (+2.91%) ▲|MCD270.44+0.13 (+0.05%) ▲|MDLZ59.17+1.33 (+2.29%) ▲|MDT79.40+1.17 (+1.50%) ▲|META618.43+55.14 (+9.79%) ▲|MMM161.68-0.23 (-0.14%) ▼|MO71.96+0.01 (+0.01%) ▲|MRK126.59-1.91 (-1.49%) ▼|MS211.51+2.47 (+1.18%) ▲|MSFT384.67+11.65 (+3.12%) ▲|MU1,053.73-100.57 (-8.71%) ▼|NEE86.95-0.82 (-0.93%) ▼|NFLX73.39+1.99 (+2.78%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.65+6.37 (+6.42%) ▲|NVDA196.89-3.20 (-1.60%) ▼|ORCL145.11-1.44 (-0.98%) ▼|PEP140.05+4.65 (+3.43%) ▲|PFE23.94-0.15 (-0.60%) ▼|PG146.37-0.27 (-0.18%) ▼|PLTR127.19+10.52 (+9.02%) ▲|PM178.43-2.48 (-1.37%) ▼|QCOM185.52+0.73 (+0.39%) ▲|RTX191.39+1.66 (+0.87%) ▲|SBUX101.57-0.63 (-0.61%) ▼|SCHW94.40+2.13 (+2.31%) ▲|SO95.79+0.08 (+0.08%) ▲|SPG221.82-1.84 (-0.82%) ▼|T20.64-0.06 (-0.29%) ▼|TMO520.60+19.24 (+3.84%) ▲|TMUS172.53+4.80 (+2.86%) ▲|TSLA429.34+8.74 (+2.08%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.35+1.19 (+1.65%) ▲|UNH421.65+6.02 (+1.45%) ▲|UNP276.15+4.15 (+1.53%) ▲|UPS109.83+2.33 (+2.17%) ▲|USB61.98+1.58 (+2.62%) ▲|V352.39+9.30 (+2.71%) ▲|VZ42.08-0.27 (-0.63%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.05-5.21 (-4.60%) ▼|XOM136.85+0.13 (+0.10%) ▲|
29 C
New York
Wednesday, July 1, 2026

Tag: stage

newssourceFORcompanyinformationcontent1releasesmarket

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Bitget Wallet Joins Malaysia Blockchain Week as Web3 Gains Ground in the Multicultural Market

Bitget Wallet, the leading non-custodial crypto wallet, joined founders, builders, and investors at Malaysia Blockchain Week to explore the country's gro..

Davis Commodities Reviews Bitcoin Reserve Model and Tokenized ESG Infrastructure Amid $16 Trillion Digital Asset Surge

Davis Commodities reviews Bitcoin reserves and tokenized ESG assets, targeting $16T RWA market with blockchain-driven capital strategies.

GR Silver Mining Extends Silver Mineralization with Step-Out Drilling at San Marcial 11.9 m @ 226 g/t Ag Eq* including 0.9m @ 716 g/t...

VANCOUVER, BC, July 25, 2025 /CNW/ - GR Silver Mining Ltd. ("GR Silver Mining" or the "Company") (TSXV: GRSL) (OTCQB: GRSLF) (FRANKFURT: GPE) – is pleased...

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed 
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its second-quarter 2025 financial results on Wednesday, Aug. 5, 2025, prior to the open of the U.S. financial markets.

First Citizens BancShares Reports Second Quarter 2025 Earnings, Announces Additional Share Repurchase Plan

RALEIGH, N.C., July 25, 2025 /PRNewswire/ -- First Citizens BancShares, Inc. ("BancShares") (Nasdaq: FCNCA) reported earnings for the second quarter of 2025.  ...

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

SUZHOU, China, July 25, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the...

Bitcoin Swift Presale Enters Final 24 Hours of Stage 1 with Token Fixed at $1

Stage 2 Will Introduce Price Increase and APY Adjustment as Project Prepares for Solana Deployment and AI-Driven Governance Rollout

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers